Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-03 01:13 | 2025-12-30 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | Pharmaceutical Preparations | SALE | $0.64 | 27 | $17 | 0 | -100.0% |
| 2025-11-25 01:08 | 2025-11-20 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | Pharmaceutical Preparations | BUY | $0.75 | 5,000 | $3,741 | 5,015 | +33,333.3% |
| 2023-05-24 00:53 | 2023-05-22 | OMER | OMEROS CORP | HANISH ARNOLD C | Director | Pharmaceutical Preparations | OPT+S | $6.46 | 5,000 | $32,300 | 0 | -100.0% |
| 2022-06-07 03:33 | 2022-06-03 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | Pharmaceutical Preparations | BUY | $0.18 | 28,000 | $5,152 | 46,350 | +152.6% |
| 2021-08-11 23:08 | 2021-08-10 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | Pharmaceutical Preparations | BUY | $0.88 | 7,000 | $6,167 | 18,350 | +61.7% |
| 2020-08-24 15:08 | 2020-08-21 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | Pharmaceutical Preparations | BUY | $0.98 | 4,000 | $3,920 | 11,350 | +54.4% |
| 2020-02-13 05:33 | 2020-02-11 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | Pharmaceutical Preparations | BUY | $1.15 | 4,350 | $5,003 | 7,350 | +145.0% |
| 2020-02-13 05:27 | 2019-11-25 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | Pharmaceutical Preparations | BUY | $3.59 | 3,000 | $10,770 | 3,000 | +100.0% |
| 2019-11-26 16:47 | 2019-11-25 | SLRX | Decoy Therapeutics Inc. | HANISH ARNOLD C | Director | Pharmaceutical Preparations | BUY | $3.59 | 3,000 | $10,770 | 6,000 | +100.0% |
| 2013-01-04 02:53 | 2013-01-03 | OMER | OMEROS CORP | HANISH ARNOLD C | Director | Pharmaceutical Preparations | BUY | $5.58 | 2,000 | $11,160 | 2,400 | +500.0% |
| 2012-05-21 22:20 | 2012-05-18 | LLY | ELI LILLY & Co | HANISH ARNOLD C | Officer; Chief Accounting Officer | Pharmaceutical Preparations | SALE | $40.49 | 1,295 | $52,435 | 17,747 | -6.8% |
| 2011-05-18 21:01 | 2011-05-17 | LLY | ELI LILLY & Co | HANISH ARNOLD C | Officer; Chief Accounting Officer | Pharmaceutical Preparations | SALE | $39.12 | 3,378 | $132,147 | 17,045 | -16.5% |
| 2009-11-23 20:55 | 2009-11-20 | LLY | ELI LILLY & Co | HANISH ARNOLD C | Officer; Chief Accounting Officer | Pharmaceutical Preparations | SALE | $36.65 | 2,673 | $97,965 | 14,105 | -15.9% |
| 2007-05-03 23:14 | 2007-05-02 | LLY | ELI LILLY & Co | HANISH ARNOLD C | Officer; Chief Accounting Officer | Pharmaceutical Preparations | SALE | $59.39 | 1,565 | $92,945 | 13,213 | -10.6% |
| 2006-09-19 21:12 | 2006-09-18 | LLY | ELI LILLY & Co | HANISH ARNOLD C | Officer; Chief Accounting Officer | Pharmaceutical Preparations | OPT+S | $54.78 | 1,250 | $68,475 | 14,186 | -8.1% |
| 2005-09-19 21:43 | 2005-09-15 | LLY | ELI LILLY & Co | HANISH ARNOLD C | Officer; Chief Accounting Officer | Pharmaceutical Preparations | OPT+S | $55.45 | 2,864 | $158,809 | 11,900 | -19.4% |
| 2003-08-19 21:16 | 2003-08-15 | LLY | ELI LILLY & Co | HANISH ARNOLD C | Officer; Chief Accounting Officer | Pharmaceutical Preparations | SALE | $61.67 | 5,000 | $308,350 | 12,737 | -28.2% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.